Safety and efficacy of non-medical switch from innovator to generic tofacitinib: a 3-month observational study in rheumatoid arthritis patients

Aim

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation. Following the expiry of the patent for innovator tofacitinib (Xeljanz), generic tofacitinib formulations such as Tozib have become available. This study evaluated the impact of a non-medical switch from innovator tofacitinib to generic tofacitinib on disease activity and flare rates over 3 months in patients with RA.